indazoles and hki 272
indazoles has been researched along with hki 272 in 3 studies
Research
Studies (3)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Buijsman, RC; de Man, J; de Roos, JA; de Vetter, JR; Prinsen, MB; Spijkers-Hagelstein, JA; Uitdehaag, JC; van Doornmalen, AM; Zaman, GJ | 1 |
| Avogadri-Connors, F; Booth, L; Cutler, RE; Dent, P; Lalani, AS; Poklepovic, A; Roberts, JL; Samuel, P | 1 |
| Basaga, H; Gul, O; Karakas, B; Kutuk, O; Ozmay, Y | 1 |
Other Studies
3 other study(ies) available for indazoles and hki 272
| Article | Year |
|---|---|
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aza Compounds; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Melanoma; Molecular Targeted Therapy; Mutation; Oxazoles; Oximes; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Quinolines; Sulfonamides; Triazoles; Vemurafenib | 2015 |
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinolines | 2018 |
Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
Topics: bcl-X Protein; Benzothiazoles; Biphenyl Compounds; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Isoquinolines; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolinones; Quinolines; Receptor, ErbB-2; Sulfonamides | 2018 |